It's important to note that breast cancer has many subtypes, and early diagnosis can significantly impact treatment costs and outcomes. Some subtypes of breast cancer are more expensive to treat, and the cost increases with the cancer stage at diagnosis. Refer to Table 1 for details.
From 2010 to 2017 in Canada, excluding Quebec, 74% of breast cancer cases were hormone receptor-positive (HR+). Other types included HR+/HER2+ (10.4%), HER2+ (4.9%), and triple-negative (TN) (10.7%).
No country can afford to treat its way out of the cancer problem: a balanced, integrated approach to prevention, early detection and treatment is required.
 -WHO: International Agency for Research on Cancer